Anzeige
Meldung des Tages: Wegweisende News: NurExone – Pionier der regenerativen neuronalen Medizin!

Atara Biotherapeutics News

Aktie
WKN:  A40DQJ ISIN:  US0465132068 US-Symbol:  ATRA Branche:  Biotechnologie Land:  USA
5,42 $
-0,36 $
-6,23%
4,5861 € 27.02.26
Depot/Watchlist
Marktkapitalisierung *
70,71 Mio. €
Streubesitz
19,86%
KGV
-
Index-Zuordnung
-

Atara Biotherapeutics News

12.02.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
29.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
22.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
03.11.25 - PR Newswire
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-​Barr Virus ...
24.07.25 - PR Newswire
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-​Barr ...
15.07.25 - PR Newswire
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. PR Newswire

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »